US2019151251A1PendingUtilityA1
Targeted Therapeutic Nanoparticles And Methods Of Making And Using Same
Est. expiryJul 3, 2034(~7.9 yrs left)· nominal 20-yr term from priority
Inventors:Hong Wang
A61P 35/00A61K 31/427A61K 9/5153A61K 9/5161A61K 9/5123A61K 9/5138A61K 31/282A61K 31/475A61K 31/337A61K 47/34B82Y 5/00A61K 47/10A61K 31/415A61K 9/141
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described herein are polymeric nanoparticles that include a therapeutic agent, and methods of making and using such therapeutic nanoparticles. In some embodiments, the contemplated nanoparticles may include an excipient.
Claims
exact text as granted — not AI-modified1 . A therapeutic nanoparticle comprising:
about 0.05 to about 30 weight percent of an excipient selected from the group consisting of a polyanionic polymer and a polycationic polymer; about 0.2 to about 35 weight percent of a therapeutic agent; and about 35 to about 99.75 weight percent of a biocompatible polymer.
2 . The therapeutic nanoparticle of claim 1 , wherein the excipient is a polyanionic polymer.
3 . The therapeutic nanoparticle of claim 2 , wherein the polyanionic polymer is a copolymer of methacrylic acid and methyl methacrylate subunits.
4 . The therapeutic nanoparticle of claim 3 , wherein the ratio of methacrylic acid to methyl methacrylate subunits is between about 1:0.9 to about 1:3.
5 . The therapeutic nanoparticle of claim 1 , wherein the excipient is a polycationic polymer.
6 . The therapeutic nanoparticle of claim 5 , wherein the polycationic polymer is a copolymer of alkyl methacrylate and dimethylaminoethylmethacrylate.
7 . The therapeutic nanoparticle of claim 6 , wherein the polycationic polymer is a copolymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate subunits.
8 . The therapeutic nanoparticle of claim 7 , wherein the ratio of dimethylaminoethyl methacrylate to butyl methacrylate to methyl methacrylate subunits is about 1:2:1.
9 . The therapeutic nanoparticle of claim 1 , wherein the excipient has a molecular weight of between about 20 kDa and about 60 kDa.
10 . The therapeutic nanoparticle of claim 1 , wherein the excipient has a molecular weight of between about 100 kDa and about kDa.
11 . The therapeutic nanoparticle of claim 1 , wherein the excipient has a glass transition temperature of between about 40° C. and about 50° C.
12 . The therapeutic nanoparticle of claim 1 , wherein the excipient has a glass transition temperature of greater than about 100° C.
13 . The therapeutic nanoparticle of claim 1 , comprising about 5 to about 25 weight percent of the excipient.
14 . The therapeutic nanoparticle of claim 1 , further comprising about 0.05 to about 35 weight percent cyclodextrin.
15 . The therapeutic nanoparticle of claim 14 , comprising about 15 to about 30 weight percent cyclodextrin.
16 . The therapeutic nanoparticle of claim 14 wherein the cyclodextrin is selected from the group consisting of α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and mixtures thereof.
17 . The therapeutic nanoparticle of claim 1 , wherein the therapeutic agent is a chemotherapeutic agent.
18 . The therapeutic nanoparticle of claim 17 , wherein the chemotherapeutic agent is selected from the group consisting of docetaxel, vincristine, vinorelbine, an epothilone, epothilone B, fluorouracil, irinotecan, capecitabine, and oxaliplatin.
19 . The therapeutic nanoparticle of claim 1 , wherein the therapeutic agent is a celecoxib.
20 . The therapeutic nanoparticle of claim 1 , comprising about 3 to about 20 weight percent of the therapeutic agent.
21 - 64 . (canceled)Join the waitlist — get patent alerts
Track US2019151251A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.